Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Rocketman who wrote (753)	10/23/1998 5:02:00 PM
From: George Sepetjian	Read Replies (1) \| Respond to of 3202

WSJ-Heard on the Street Agouron, Others Could Benefit From Consolidation, WSJ Reports New York, Oct. 23 (Bloomberg) - Agouron Pharmaceuticals Inc., Alkermes Inc. and Aviron are among biotechnology stocks that Oracle Partners LP owns that could benefit from consolidation in the industry, the Wall Street Journal reported in its ''Heard on the Street'' column, citing Larry Feinberg, a principal with Oracle. IDEC Pharmaceuticals Corp., Incyte Pharmaceuticals Inc., MedImmune Inc., PathoGenesis Corp. and Texas Biotechnology Corp. could also benefit, said Feinberg, whose hedge funds specializing in health care have about 40 percent of their money in biotech stocks. Feinberg predicts ''the biggest biotech rally'' ever by year end or early 1999, with investors moving to ''a new valuation paradigm'' for small- capitalization biotech stocks based on the amount larger companies will pay for them, not earnings a share, the paper said.